The NUB reimbursement pathway has been effective in bringing high-cost innovative medical technologies to the German market, but there are challenges. In MedTech Strategist, we assess the funding of medtech through NUBs and outlines the strengths and weaknesses of the NUB pathway.
ASCO 2025 review: Assessing complex choices, optimizing outcomes, and prioritizing patients
Several pivotal topics emerged, establishing predominant themes throughout the conference. Although efficacy continues to be the fundamental basis of oncology...